CVS CEO's Conservative Approach Wins Wall Street Favor
CVS Health (CVS) shares surged nearly 15% on Wednesday, buoyed by Wall Street's approval of CEO David Joyner's cautious 2025 financial outlook.
Strong Earnings, Prudent Guidance
CVS reported $372.8 billion in full-year 2024 revenue, exceeding Wall Street's $96.8 billion estimate. Fourth-quarter earnings totaled $97.7 billion. For 2025, while full-year revenue guidance was not provided, CVS estimated adjusted earnings per share to be between $5.75 and $6.
Joyner's conservative approach aims to restore investor confidence following previous challenges, including higher-than-expected healthcare utilization.
JPMorgan's Positive View
Analysts remain bullish on CVS. JPMorgan's Lisa Gill praised Joyner's "degree of conservatism" and "positive view" post-earnings.
PBMs Under Scrutiny
Despite a strong start to the year, Joyner acknowledged ongoing challenges in the pharmacy benefit manager (PBM) sector. Congress is investigating PBMs for their role in healthcare costs.
Joyner Defends PBM Role
Joyner defended the value of PBMs in reducing drug prices. CVS is shifting its PBM strategy to a flat-rate plus markup model, similar to Mark Cuban's Cost Plus Drugs.
CVS Innovates to Create Efficiencies
Joyner believes CVS's combination of its new PBM strategy and healthcare services will lead to greater efficiency. He said the company has "changed the market" by driving pricing formula rationalization.
Industry Insights from Anjalee Khemlani
Follow Yahoo Finance's senior health reporter Anjalee Khemlani (@AnjKhem) for up-to-date industry news and analysis on pharma, insurance, and healthcare policy.